As of May 04, 2026, Allogene Therapeutics's top three insider holders are David D Chang (President And Ceo, 5.15Mn shares), David D Chang (President And Ceo, 5.15Mn shares), Arie Belldegrun (Director, 2.24Mn shares).
| Holder | Position | Shares (Direct) | Shares (Indirect) | Report Date |
|---|---|---|---|---|
| David D Chang | President And Ceo | 5,150,599 | 0 | 18 Mar, 2026 |
| David D Chang | President And Ceo | 5,150,599 | 0 | 18 Mar, 2026 |
| Arie Belldegrun | - | 2,236,816 | 0 | 28 Jan, 2025 |
| Arie Belldegrun | - | 0 | 1,724,137 | 20 May, 2024 |
| Geoffrey M. Parker | Chief Financial Officer | 1,252,795 | 0 | 04 Feb, 2026 |
| Geoffrey M. Parker | Chief Financial Officer | 1,252,795 | 0 | 04 Feb, 2026 |
| Eric Thomas Schmidt | Chief Financial Officer | 862,439 | 0 | 24 Mar, 2023 |
| Eric Thomas Schmidt | Chief Financial Officer | 862,439 | 0 | 24 Mar, 2023 |
| Alison Moore | Chief Technical Officer | 672,731 | 0 | 24 Mar, 2023 |
| Alison Moore | Chief Technical Officer | 672,731 | 0 | 24 Mar, 2023 |
| Zachary Roberts | Evp Of Rd | 581,166 | 0 | 04 Feb, 2026 |
| Zachary Roberts | Evp Of Rd | 581,166 | 0 | 04 Feb, 2026 |
| Earl Martin Douglas | Svp, General Counsel | 564,948 | 0 | 04 Feb, 2026 |
| Earl Martin Douglas | Svp, General Counsel | 564,948 | 0 | 04 Feb, 2026 |
| Veer Bhavnagri | General Counsel | 556,049 | 0 | 16 Mar, 2023 |
| Veer Bhavnagri | General Counsel | 556,049 | 0 | 16 Mar, 2023 |
| Rafael Amado | Evp Of Rd | 541,946 | 0 | 11 Oct, 2022 |
| Joshua A Kazam | - | 350,763 | 0 | 22 Dec, 2025 |
| Franz B Humer | - | 307,507 | 0 | 09 Dec, 2024 |
| Owen N. Witte | - | 292,832 | 0 | 15 Jun, 2023 |
| Owen N. Witte | - | 292,832 | 0 | 15 Jun, 2023 |
| Timothy L. Moore | Chief Technical Officer | 250,713 | 0 | 05 Feb, 2025 |
| Timothy L. Moore | Chief Technical Officer | 250,713 | 0 | 05 Feb, 2025 |
| Benjamin Machinas Beneski | Svp, Chief Technical Officer | 195,338 | 0 | 02 Apr, 2026 |
| Benjamin Machinas Beneski | Svp, Chief Technical Officer | 195,338 | 0 | 02 Apr, 2026 |
| Vicki L Sato | - | 162,575 | 0 | 07 Jun, 2024 |
| Lillian Smith | Vp, Corporate Counsel | 140,390 | 0 | 05 Apr, 2023 |
| Lillian Smith | Vp, Corporate Counsel | 140,390 | 0 | 05 Apr, 2023 |
| Annie Yoshiyama | Svp, Finance | 130,322 | 0 | 04 Feb, 2026 |
| Annie Yoshiyama | Svp, Finance | 124,517 | 0 | 23 Apr, 2026 |
| Deborah M. Messemer | - | 107,431 | 0 | 12 Jun, 2025 |
| Yinlin Jack Chen | Svp, Finance | 88,881 | 0 | 14 Aug, 2023 |
| Yinlin Jack Chen | Svp, Finance | 88,881 | 0 | 14 Aug, 2023 |
| Stephen Mayo | - | 25,328 | 0 | 09 Aug, 2023 |
| Stephen Mayo | - | 25,328 | 0 | 09 Aug, 2023 |
* Please note that the shares above only reflect shares from the fund portfolio and the institutional portfolio. Shares from the personal portfolio are excluded from this Institutional Ownership Page. See these insiders' latest transactions here on Insider Page.
| Transaction Date | Insider Name | Security Class | Transaction Type | Shares Traded | Price | Shares Remaining | Ownership | Code |
|---|---|---|---|---|---|---|---|---|
| 21 Apr, 2026 | Annie Yoshiyama | Common Stock | D | 9,586 | $2.31 | 124,517 | D | S |
| 21 Apr, 2026 | Annie Yoshiyama | Common Stock | D | 9,586 | $2.31 | 124,517 | D | S |
| 21 Apr, 2026 | Annie Yoshiyama | Common Stock | D | 9,586 | $2.31 | 124,517 | D | S |
| 21 Apr, 2026 | Annie Yoshiyama | Common Stock | D | 9,586 | $2.31 | 124,517 | D | S |
| 21 Apr, 2026 | Annie Yoshiyama | Common Stock | D | 9,586 | $2.31 | 124,517 | D | S |
| 31 Mar, 2026 | Benjamin Machinas Beneski | Common Stock | D | 2,867 | $2.50 | 195,338 | D | S |
| 16 Mar, 2026 | Benjamin Machinas Beneski | Common Stock | D | 4,835 | $2.47 | 198,205 | D | S |
| 16 Mar, 2026 | David D Chang | Common Stock | D | 47,763 | $2.47 | 5,150,599 | D | S |
| 02 Mar, 2026 | Benjamin Machinas Beneski | Common Stock | D | 7,132 | $2.60 | 203,040 | D | S |
| 02 Feb, 2026 | David D Chang | Common Stock | D | 95,269 | $1.80 | 5,185,862 | D | S |
| 02 Feb, 2026 | Earl Martin Douglas | Common Stock | D | 22,900 | $1.76 | 564,948 | D | S |
| 02 Feb, 2026 | Zachary Roberts | Common Stock | D | 35,700 | $1.77 | 581,166 | D | S |
| 02 Feb, 2026 | Annie Yoshiyama | Common Stock | D | 4,167 | $1.72 | 130,322 | D | S |
| 02 Feb, 2026 | Benjamin Machinas Beneski | Common Stock | D | 7,549 | $1.73 | 210,172 | D | S |
| 02 Feb, 2026 | Geoffrey M. Parker | Common Stock | D | 24,001 | $1.76 | 1,252,795 | D | S |
| 02 Feb, 2026 | Annie Yoshiyama | Stock Option (Right to buy) | A | 179,691 | $0.00 | 179,691 | D | A |
| 02 Feb, 2026 | Benjamin Machinas Beneski | Stock Option (Right to buy) | A | 373,757 | $0.00 | 373,757 | D | A |
| 02 Feb, 2026 | Earl Martin Douglas | Stock Option (Right to buy) | A | 539,072 | $0.00 | 539,072 | D | A |
| 02 Feb, 2026 | Zachary Roberts | Stock Option (Right to buy) | A | 718,763 | $0.00 | 718,763 | D | A |
| 02 Feb, 2026 | Geoffrey M. Parker | Stock Option (Right to buy) | A | 539,072 | $0.00 | 539,072 | D | A |